Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 20, 2024

Efficacy of Nirmatrelvir–Ritonavir in Reducing the Severity of Postacute Sequelae of SARS-CoV-2 Infection in Adults

JAMA Internal Medicine


Additional Info

JAMA Internal Medicine
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial
JAMA Intern Med 2024 Jun 07;[EPub Ahead of Print], LN Geng, H Bonilla, H Hedlin, KB Jacobson, L Tian, P Jagannathan, PC Yang, AK Subramanian, JW Liang, S Shen, Y Deng, BJ Shaw, B Botzheim, M Desai, D Pathak, Y Jazayeri, D Thai, A O'Donnell, S Mohaptra, Z Leang, GZM Reynolds, EF Brooks, AS Bhatt, RW Shafer, MG Miglis, T Quach, A Tiwari, A Banerjee, RN Lopez, M De Jesus, LR Charnas, PJ Utz, U Singh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading